As cancer cells grow, they pump out metabolic byproducts such as lactic acid into the tumor microenvironment. Exhausted T ...

CAR T-cell therapies for hematologic malignancies ... coupled with other mutations that create a heterogeneous target." ...

Researchers say study offers proof-of-concept that targeting how T cells interact with metabolites in their environment can ...

Researchers advance CAR T cell therapy for solid tumors by innovating ways to overcome the unique barriers of solid tumor ...

By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...

Researchers have developed an innovative CAR T-cell therapy to combat glioblastoma, the most common malignant brain tumor in ...

One-third of HER2-positive (HER2+) tumors express the P95HER2 protein, which associates with an aggressive form of breast ...

A study at MedUni Vienna's Department of Dermatology provides insights into the diversity of cancer-associated fibroblasts in ...

New research provides insights into the diversity of cancer-associated fibroblasts in white and black skin cancer and ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...

CAR T-cell therapy shows promise for solid tumors like glioblastoma. New engineering strategies and clinical trial results ...

Researchers at the University of Basel and University Hospital Basel have now developed an immunotherapy that not only attacks the tumor -- it also turns its microenvironment against it. For some ...